Table 1.
Data summary for the mutation samples from TCGA, UK BioBank and cBioPortal datasets. The “Total Samples” is with respect to the samples associated with the genes of interest.
| Gene | Samples | TCGA | UK BioBank | cBioPortal |
|---|---|---|---|---|
| Total Samples | 713 | 950 | 647 | |
| All cancers | 713 (100%) | 48 (100%) | 647 (100%) | |
| Female cancers * | 145 (20.33%) | 7 (14.58%) | 208 (32.14%) | |
| GBP5 | All cancers Female cancers |
145 (20.33%) 27 (3.78%) |
3 (6.25%) 1 (2.08%) |
150 (23.18%) 54 (8.34%) |
| IRS2 | All cancers Female cancers |
114 (15.98%) 30 (4.20%) |
8 (16.66%) - |
82 (12.67%) 18 (2.78%) |
| KRT4 | All cancers Female cancers |
154 (21.59%) 22 (3.08%) |
7 (14.58%) 2 (4.16%) |
158 (24.42%) 50 (7.72%) |
| LINC00707 | All cancers Female cancers |
- - |
24 (50%) 2 (4.16%) |
- - |
| MRPL55 | All cancers Female cancers |
35 (4.90%) 10 (1.40%) |
1 (2.08%) 1 (2.08%) |
24 (3.70%) 9 (1.39%) |
| RRS1 | All cancers Female cancers |
57 (7.99%) 16 (2.24%) |
1 (2.08%)- | 38 (5.87%) 11 (1.70%) |
| SLC4A11 | All cancers Female cancers |
208 (29.17%) 40 (5.61%) |
4 (8.33%) 1 (2.08%) |
195 (30.13%) 67 (10.35%) |
* Female cancers: ovarian, cervical/endocervical, uterine, breast and endometrial/uterine corpus endometrioid carcinoma.